FibroGen Hails 'Milestone' IPF Data, Phase III And Partners Beckon
Phase II data for FibroGen's first-in-class therapy for idiopathic pulmonary fibrosis panrevlumab has sent its shares soaring and could have potential partners scrambling.
Phase II data for FibroGen's first-in-class therapy for idiopathic pulmonary fibrosis panrevlumab has sent its shares soaring and could have potential partners scrambling.